Regeneron Pharmaceuticals, Inc.
REGN
$589.48
-$8.68-1.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 72.08% | -11.88% | -31.55% | -6.40% | 98.38% |
| Total Depreciation and Amortization | 6.46% | 0.40% | 3.86% | 0.83% | 5.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -668.16% | -106.59% | 384.61% | 63.10% | -223.15% |
| Change in Net Operating Assets | -275.85% | 250.00% | -35.21% | 92.97% | -306.24% |
| Cash from Operations | 9.50% | -17.24% | -2.20% | 264.75% | -76.60% |
| Capital Expenditure | 4.49% | -14.88% | 17.49% | -34.02% | -34.80% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | 100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -199.79% | 56.10% | 268.93% | 15.14% | 74.77% |
| Cash from Investing | -268.96% | 84.68% | 161.04% | -3.09% | 66.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -48.02% | -33.33% | -64.31% | -41.80% | -35.85% |
| Repurchase of Common Stock | -2.05% | 14.73% | -43.39% | 6.60% | -44.20% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 1.28% | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | 100.00% | -- | -- |
| Cash from Financing | -3.58% | 4.08% | -79.10% | -32.61% | -1,115.07% |
| Foreign Exchange rate Adjustments | -33.33% | 185.71% | -187.50% | 366.67% | 40.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -278.38% | 26.57% | 470.81% | 112.27% | -432.50% |